CORE Reference Seminar - EMWA Valencia May 2024 and Webinar 07 June 2024 meeting chat.

13:00:33 Hi Sam, I have a question. Do you/the team have any further advise or guidance to consult on interacting with the regulatory authorities in the situation of a rare disease? When/how should this be done? Many thanks.

13:00:56 Regarding the quantitative anonymization approach. Are you using a vendor to calculate risk insert age banding, etc? Or have you invested in these capabilities in house?

https://journal.emwa.org/public-disclosure/preparing-anonymisation-reports-in-general-and-for-an-orphan-drug-in-particular/article/3795/martinsson_preparing-anonymisation-reports-ingeneral-and-for-an-orphan-drug-inparticular.pdf